Literature DB >> 7844814

Site-specific recombination at res sites containing DNA-binding sequences for both Tn21 resolvase and CAP.

P Soultanas1, S E Halford.   

Abstract

The res sites, the loci for site-specific recombination by resolvase, contain three binding sites for the protein; the cross-over site, I, and accessory sites II and III. The role of DNA bending by resolvase was examined by replacing either II or III in the res site from Tn21 with the recognition sequence for a heterologous DNA-bending protein, CAP (the catabolite-gene activator protein from Escherichia coli). The CAP sequence was placed at either the same position as the target sequence for Tn21 resolvase or a different position along the DNA. The activity of Tn21 resolvase for recombination between each hybrid and a wild-type res site was measured in the presence of CAP and cyclic AMP. When III was substituted, CAP inhibited Tn21 recombination, except when the CAP sequence was placed sufficiently far away from site II to allow resolvase to bind non-specifically to the DNA between II and the CAP site. With the substitutions at II, the extent of Tn21 recombination in the presence of CAP varied with the position of the CAP sequence: more recombination was observed when it superimposed the target sequence for resolvase than when it was displaced by five base-pairs. Efficient recombination by Tn21 resolvase thus seems to demand the cognate protein at site III in res, presumably for protein-protein interactions in the synaptic complex, while the function of resolvase at site II can be fulfilled, at least in part, by a heterologous DNA bend.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844814     DOI: 10.1006/jmbi.1994.0018

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  1 in total

1.  Architecture of a serine recombinase-DNA regulatory complex.

Authors:  Kent W Mouw; Sally-J Rowland; Mark M Gajjar; Martin R Boocock; W Marshall Stark; Phoebe A Rice
Journal:  Mol Cell       Date:  2008-04-25       Impact factor: 17.970

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.